RIGAS STRADINA UNIVERSITATE

Their core work

Riga Stradiņš University (RSU) is Latvia's leading medical university, specializing in infectious disease diagnostics, biomarker research, and translational medicine. They contribute clinical expertise and patient cohort access to European health research consortia, particularly in febrile illness management, autoimmune diseases, and human biomonitoring. Beyond health, RSU is building a Baltic Biomaterials Centre of Excellence and participates in media and social policy research, reflecting its broader role as a multidisciplinary academic institution in the Baltic region.

What they specialise in

How they've shifted over time

In their early H2020 period (2015-2018), RSU focused on building research capacity through twinning (VACTRAIN on cancer vaccines) and joined health consortia on antibiotic resistance, febrile illness, and public health systems. From 2020 onward, their work shifted decisively toward molecular diagnostics, personalised medicine infrastructure (EATRIS-Plus), and establishing the Baltic Biomaterials Centre of Excellence as a long-term institutional asset. The trajectory shows a university moving from capacity-building participant to regional research hub with its own diagnostic and translational medicine agenda.

RSU is positioning itself as the Baltic region's translational medicine hub, combining diagnostic algorithm development with biomaterials expertise and European research infrastructure membership.

How they like to work

RSU operates overwhelmingly as a consortium partner (11 of 13 projects), contributing clinical and biomedical expertise to large European consortia rather than leading them. Their two coordinator roles — VACTRAIN (twinning) and VirA (networking) — are both Widening Participation instruments designed to strengthen their own institutional capacity, not to lead major research agendas. With 240 unique partners across 42 countries, they are well-networked and open to diverse collaborations, making them an accessible partner for consortia needing Baltic clinical sites or biomedical research capacity.

RSU has collaborated with 240 unique partners across 42 countries, an exceptionally broad network for a mid-sized university. This reach reflects their participation in large pan-European health initiatives (HBM4EU, EATRIS-Plus, DIAMONDS) rather than repeated partnerships with a small circle.

What sets them apart

RSU is the strongest biomedical research university in the Baltic states with direct access to clinical patient cohorts and a growing biomaterials centre of excellence. For consortium builders, they offer something rare: a Widening Country partner that brings genuine clinical research capacity, not just geographic diversity for proposal scoring. Their dual focus on infectious disease diagnostics and biomaterials creates unusual cross-disciplinary potential that few single institutions can offer.

Highlights from their portfolio

• BBCE
  Their largest investment (EUR 915K) — a long-running Centre of Excellence in biomaterials and medical devices, signaling a major institutional commitment through 2027.
• DIAMONDS
  EUR 520K for RNA-based personalised molecular diagnosis of febrile illness — represents their most advanced diagnostic research and runs through 2026.
• VirA
  One of only two projects RSU coordinated, focused on closing the gap between RSU and leading virology/autoimmune research centres using multiplex diagnostic technologies.